High-frequency point mutations of genes encoding histones have been identified recently as novel drivers in a number of tumors. Specifically, the H3K36M/I mutations were shown to be oncogenic in chondroblastomas and undifferentiated sarcomas by inhibiting H3K36 methyltransferases, including SETD2. Here we report the crystal structures of the SETD2 catalytic domain bound to H3K36M or H3K36I peptides with SAH (S-adenosylhomocysteine). In the complex structure, the catalytic domain adopts an open conformation, with the K36M/I peptide snuggly positioned in a newly formed substrate channel. Our structural and biochemical data reveal the molecular basis underying oncohistone recognition by and inhibition of SETD2.Supplemental material is available for this article.Received May 16, 2016; revised version accepted June 20, 2016. Histone post-translational modifications (PTMs) are linked to tumorigenesis, mostly via dysfunction of their regulators (e.g., readers, writers, and erasers) that are frequently mutated in tumors (Dawson and Kouzarides 2012). Recently, high-frequency mutations in genes encoding histones themselves, rather than the histone regulators, were identified in a number of cancer types. Exome sequencing studies have identified recurrent hot spot missense mutations in histone H3. Notably, these mutations are located at or adjacent to H3 lysine residues that undergo acetylation and/or methylation. For example, the H3K27M mutation was identified in the majority of pediatric diffuse intrinsic pontine gliomas (Schwartzentruber et al. 2012;Wu et al. 2012), and the H3K36M mutation was found to occur predominantly in chondroblastomas (Behjati et al. 2013) and rarely in other cancer types such as head and neck squamous cell carcinoma and colorectal cancer (Shah et al. 2014). In addition, the H3K36-neighboring G34 mutations, such as G34R/V and G34W/L, have been detected in pediatric non-brain stem gliomas (Schwartzentruber et al. 2012;Wu et al. 2012) and giant cell tumors of the bone (Behjati et al. 2013), respectively.Biochemical and cellular studies showed that H3K27M reduced global H3K27 methylation in vitro and in vivo by inhibiting the methyltransferase activity of polycombrepressive complex 2 (PRC2) (Chan et al. 2013;Lewis et al. 2013;Justin et al. 2016). Recently, we and others identified a similar "poisoning" mechanism underlying H3K36M-driven tumorigenesis involving the inactivation of H3K36 methyltransferases (Fang et al. 2016;Lu et al. 2016). H3K36 can be methylated by enzymes such as NSD1/2/3, ASH1L, and SETD2 (Wagner and Carpenter 2012). Among them, SETD2 serves as the major H3K36 methyltransferase that is able to generate the trimethylated H3K36 from the unmethylated, monomethylated, or dimethylated states in vitro and in cells (Edmunds et al. 2008;Hu et al. 2010). SETD2 plays important roles in cellular processes such as transcription elongation (Yoh et al. 2008), RNA splicing (de Almeida et al. 2011;Kim et al. 2011), and DNA damage repair (Li et al. 2013;Pai et al. 2014). However, due to the lack...